试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •- Male or female
- •- Age 45-75 y
- •- BMI 25-35 kg/m2
- •- Suitable veins for insertion of cannula
排除标准
- •- Having a gastro-intestinal disease, such as celiac disease, Crohn*s disease,
- •or Ulcerative colitis
- •- Having a history of intestinal surgery that might interfere with study
- •outcomes, as determined by the medical supervisor. This does not include an
- •appendectomy or cholecystectomy
- •- Presence of significant systemic diseases, such as diabetes mellitus, cancer,
- •cardiovascular disease or respiratory disease, as determined by the medical
- •- Use of medications known to interfere with glucose or lipid homeostasis (e.g.
- •corticosteroids, cholesterol-lowering medication, insulin, metformin), as
- •determined by medical supervisor
- •- Blood clotting disorders
- •- Unstable body weight (weight gain or loss >3 kg in the past three months)
- •- Reported slimming, medically prescribed or other extreme diets
- •- Alcohol consumption >21 glasses a week
- •- Anaemia (Hb values <7.5 mmol/L for women and <8.5 mmol/L for men; checked at
- •- Pregnant, lactating or wishing to become pregnant in the period of the study
- •(self-reported)
- •- Having a pacemaker, ICD, hearing implant, internal insulin pump,
- •neurostimulator, aneurysm clips placed before 1990, or metal splinter in the eye
- •- Having claustrophobia
- •- Not willing to give up blood donation during the study
- •- Food allergies or intolerances for products that we use in the study
- •- Unwilling to consume non-vegan test meal
- •- Recent use of antibiotics (<3 months prior to study start)
- •- Current smokers
- •- Abuse of soft and/or hard drugs
- •- Participation in another clinical trial at the same time
- •- Being an employee of the Food, Health & Consumer Research group of Wageningen
- •Food & Biobased Research or Human Nutrition and Health Department of Wageningen
研究者
相似试验
已完成
不适用
A RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, COMPARATIVE, MULTICENTER STUDY TO ASSESS THE INCIDENCE OF HEMOLYSIS, SAFETY, AND EFFICACY OF TAFENOQUINE (SB-252263, WR238605) VERSUS PRIMAQUINE IN THE TREATMENT OF SUBJECTS WITH PLASMODIUM VIVAX MALARIA-B51 Plasmodium vivax malariaPlasmodium vivax malariaB51PER-048-14GlaxoSmithKline,100
进行中（未招募）
1 期
A DOUBLE BLIND, DOUBLE DUMMY, GROUP COMPARATIVE STUDY TO ASSESS THERAPEUTIC EQUIVALENCE OF A NEW GENERIC FORMOTEROL 12 uG DRY POWDER FORMULATION WITH OXIS 12uG TURBUHALER IN ADOLESCENT AND ADULT ASTHMATIC PATIENTSEUCTR2006-000683-84-SKAndi-Ventis Ltd.200
进行中（未招募）
不适用
A DOUBLE BLIND, DOUBLE DUMMY, GROUP COMPARATIVE STUDY TO ASSESS THERAPEUTIC EQUIVALENCE OF A NEW GENERIC FORMOTEROL 12 uG DRY POWDER FORMULATION WITH OXIS 12uG TURBUHALER IN ADOLESCENT AND ADULT ASTHMATIC PATIENTSEUCTR2006-000683-84-HUAndi-Ventis Ltd.200
进行中（未招募）
1 期
Chronocort versus Plenadren replacement therapy in adults with adrenal insufficiencyEUCTR2021-000144-21-DEDiurnal Limited50
进行中（未招募）
1 期
DMedDRA version: 20.0Level: SOCClassification code 10010331Term: Congenital, familial and genetic disordersSystem Organ Class: 10010331 - Congenital, familial and genetic disordersFabry diseaseEUCTR2018-000368-27-ITFONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE14